ReviewAAPS PharmSciTech2026
Smart In Situ-Forming Ocular Therapeutics for Dry Eye Disease: Bridging Biomaterials, Nanotechnology, and Clinical Translation.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a multifactorial inflammatory condition of the ocular surface that significantly impairs quality of life through tear film instability and chronic irritation. Despite the prevalence of DED, conventional topical therapies are hindered by poor ocular bioavailability (< 7%) due to rapid precorneal clearance and restrictive anatomical barriers. Stimuli-responsive in situ forming systems have emerged as a transformative strategy to overcome these limitations by undergoing a "sol-to-gel" transition in response to physiological triggers such as temperature, pH, or ionic strength. This review provides a comprehensive analysis of recent advancements in "smart" ocular therapeutics, specifically focusing on the integration of nanocarriers within stimuli-responsive hydrogel matrices. Furthermore, we discuss the role of redox- and enzyme-responsive platforms in addressing the oxidative stress and enzymatic imbalances characteristic of the DED microenvironment. By bridging the gap between innovative biomaterials and clinical translation, this review identifies the pathways for next-generation precision medicine in ophthalmology, offering a roadmap to improve patient compliance and long-term therapeutic outcomes in DED management.
Indexed as
Identifiers
42010011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.